Press Releases

Date   Headline
Jan 29, 2015 Cleveland BioLabs Announces Oncology Clinical Development Update for Entolimod
Jan 28, 2015 Cleveland BioLabs Announces Board Appointment
Jan 27, 2015 Cleveland BioLabs Announces Results of Special Meeting of Stockholders and Reverse Stock Split
Jan 12, 2015 Cleveland BioLabs Receives Department of Defense Support to Further Development of Entolimod (CBLB502) as a Medical Radiation Countermeasure
Jan 06, 2015 Cleveland BioLabs and Incuron Announce Updates on Clinical Progress With Curaxin CBL0137
Nov 13, 2014 Cleveland BioLabs and Roswell Park Cancer Institute Announce Publication of Studies Demonstrating Curaxin CBL0137's Ability to Eradicate Drug-Resistant Cancer Stem Cells and Potentiate Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer
Nov 05, 2014 Cleveland BioLabs Reports Third Quarter 2014 Financial Results and Development Progress
Nov 04, 2014 Cleveland BioLabs to Host Third Quarter 2014 Earnings Conference Call and Webcast Live on Wednesday, November 5, 2014
Oct 28, 2014 Cleveland BioLabs to Report Third Quarter 2014 Financial Results and Provide Operational Update on November 5
Sep 15, 2014 Cleveland BioLabs Announces Approval to Start Phase 1 Study for Hematopoietic Stem Cell Mobilizer CBLB612 in Russian Federation
Sep 08, 2014 Cleveland BioLabs and Sabby Announce Resolution of Litigation
Sep 03, 2014 Cleveland BioLabs Announces Green Light to Submit Pre-Emergency Use Authorization Application for Entolimod
Sep 02, 2014 Cleveland BioLabs to Report Outcome of July FDA Meeting and Host Conference Call on September 3
Sep 02, 2014 Cleveland BioLabs to Present at Rodman & Renshaw 16th Annual Global Investment Conference
Aug 07, 2014 Cleveland BioLabs Reports Second Quarter 2014 Financial Results and Development Progress
You are now leaving this website. If you would like to continue, click Continue.